

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
April 19, 2011

ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

**BioSante Pharmaceuticals, Inc.**  
File No. 0-28637 - CF#26545

---

**BioSante Pharmaceuticals, Inc.** submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from Exhibits 10.18, 10.19 and 10.20 to a Form 10-KSB filed on March 28, 2002. Exhibits 10.18 and 10.20 were re-filed with fewer redactions as Exhibits 10.28 and 10.30 to the Form 10-K filed on March 16, 2011.

Based on representations by **BioSante Pharmaceuticals, Inc.** that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.18 through March 31, 2015  
*(as re-filed with fewer redactions as Exhibit 10.28 to the Form 10-K filed March 16, 2011)*

Exhibit 10.19 through March 31, 2015

Exhibit 10.20 through March 31, 2015  
*(as re-filed with fewer redactions as Exhibit 10.30 to the Form 10-K filed March 16, 2011)*

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Daniel Greenspan  
Branch Chief